
Briefing · From the Watchtower
FDA approves AstraZeneca's Imfinzi plus enfortumab vedotin for perioperative MIBC
What the FDA cleared
The FDA approved durvalumab (Imfinzi) with enfortumab vedotin-ejfv as neoadjuvant treatment, then single-agent durvalumab as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy, on 13 November 2026 [1]. AstraZeneca confirmed the US approval through its newsroom [2]. The clearance sits under BLA 761069, held by AstraZeneca UK [3].
The decision-relevant change is the backbone. The neoadjuvant pairing swaps platinum chemotherapy for an antibody-drug conjugate, enfortumab vedotin, in exactly the patients who cannot receive cisplatin [1]. AstraZeneca's other perioperative bladder program, NIAGARA (NCT03732677), pairs durvalumab with gemcitabine and cisplatin chemotherapy and is active but no longer recruiting [4]. The new regimen gives the franchise a route into the cisplatin-ineligible segment that a platinum backbone cannot serve.
The evidence, and its limits
Approval rests on VOLGA (NCT04960709), a randomized, open-label trial that assigned 695 cystectomy candidates 1:1:1 to neoadjuvant durvalumab plus enfortumab vedotin then adjuvant durvalumab, radical cystectomy alone, or a third investigational combination [1]. The primary endpoint was event-free survival by blinded independent review, with overall survival as an additional outcome measure [1]. Prognyx could not confirm the magnitude of the event-free survival benefit, the overall survival result, or the safety profile from the sources in this dossier.
Who is actually exposed
The shared component is enfortumab vedotin. Summit Therapeutics disclosed HARMONi-GU1, a Phase II/III study of its ivonescimab plus enfortumab vedotin in previously untreated first-line metastatic urothelial carcinoma [6]. That is enfortumab-vedotin-combination competition in urothelial cancer, though in metastatic disease rather than the perioperative setting approved here. The marketed PD-1 and PD-L1 incumbents in urothelial cancer, pembrolizumab (Keytruda) and avelumab (Bavencio), carry metastatic and maintenance indications, not perioperative muscle-invasive disease, so the direct overlap with this approval is narrow [7][8]. Erdafitinib (Balversa) stays biomarker-selected in FGFR3-altered metastatic disease [9].
Track AstraZeneca
The next move on AstraZeneca (readout, FDA/EMA action, deal) by email, the day we publish it.
One email per briefing. Double opt-in, no open tracking. Privacy.
Compare active trials live → · Request a brief on your target →
What to watch, with dates
- Overall survival from VOLGA: listed as an additional outcome measure and not reported in this dossier [1].
- The post-approval confirmatory commitment: AstraZeneca's Phase 4 single-arm study in India (NCT07876817) is not yet open [5].
- Europe: Prognyx could not verify, from a primary EMA or company source, a reported positive CHMP opinion for Merck's pembrolizumab plus enfortumab vedotin in perioperative cisplatin-ineligible MIBC; the one pointer in this dossier is an unresolved news aggregator link.
The now-what
Three moves follow for operators in bladder and urothelial oncology. Teams designing a perioperative MIBC trial now benchmark against a chemo-free immuno-oncology plus ADC comparator in cisplatin-ineligible patients rather than a platinum-only control [1]. Groups holding enfortumab-vedotin-adjacent assets should read the approval as confirmation that the ADC is becoming a combination backbone across sponsors, from AstraZeneca here to Summit Therapeutics in metastatic disease [1][6].
Verdict: a real competitive move in cisplatin-ineligible MIBC, moderate threat to rival perioperative programs, with the window to reposition open now and narrowing as VOLGA overall survival and any EU decisions land.
The Watchtower, by email
The next move on AstraZeneca, the day it happens.
You have just read a briefing on AstraZeneca. The next readout, FDA/EMA action or deal reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Questions this briefing answers
Which patients does the new durvalumab plus enfortumab vedotin approval cover?
Adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. They receive neoadjuvant durvalumab plus enfortumab vedotin before radical cystectomy, then single-agent durvalumab afterward [1].
What trial supported the approval?
VOLGA (NCT04960709), a randomized, open-label trial that assigned 695 cystectomy candidates to the durvalumab combination, surgery alone, or a third investigational arm, with event-free survival by blinded independent review as the primary endpoint [1]. The dossier does not carry the effect size or the overall survival result.
Sources: every claim traces to the primary record
- FDA OCE, durvalumab + enfortumab vedotin-ejfv for MIBC
- AstraZeneca newsroom, Imfinzi + EV approved in US in bladder cancer
- Drugs@FDA, BLA 761069 (AstraZeneca UK Ltd)
- ClinicalTrials.gov NCT03732677 (NIAGARA)
- ClinicalTrials.gov NCT07876817 (Phase 4 confirmatory, India)
- SEC 8-K, Summit Therapeutics (HARMONi-GU1, ivonescimab + EV)
- DailyMed, KEYTRUDA (pembrolizumab) label
- DailyMed, BAVENCIO (avelumab) label
- DailyMed, BALVERSA (erdafitinib) label
How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.